Cargando…
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Centers for Disease Control and Prevention
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942308/ https://www.ncbi.nlm.nih.gov/pubmed/35298453 http://dx.doi.org/10.15585/mmwr.mm7111e1 |
| _version_ | 1784673280845676544 |
|---|---|
| author | Fowlkes, Ashley L. Yoon, Sarang K. Lutrick, Karen Gwynn, Lisa Burns, Joy Grant, Lauren Phillips, Andrew L. Ellingson, Katherine Ferraris, Maria V. LeClair, Lindsay B. Mathenge, Clare Yoo, Young M. Thiese, Matthew S. Gerald, Lynn B. Solle, Natasha Schaefer Jeddy, Zuha Odame-Bamfo, Leah Mak, Josephine Hegmann, Kurt T. Gerald, Joe K. Ochoa, Jezahel S. Berry, Mark Rose, Spencer Lamberte, Julie Mayo Madhivanan, Purnima Pubillones, Felipe A. Rai, Ramona P. Dunnigan, Kayan Jones, John T. Krupp, Karl Edwards, Laura J. Bedrick, Edward J. Sokol, Brian E. Lowe, Ashley McLeland-Wieser, Hilary Jovel, Krystal S. Fleary, Deanna E. Khan, Sana M. Poe, Brandon Hollister, James Lopez, Joanna Rivers, Patrick Beitel, Shawn Tyner, Harmony L. Naleway, Allison L. Olsho, Lauren E.W. Caban-Martinez, Alberto J. Burgess, Jefferey L. Thompson, Mark G. Gaglani, Manjusha |
| author_facet | Fowlkes, Ashley L. Yoon, Sarang K. Lutrick, Karen Gwynn, Lisa Burns, Joy Grant, Lauren Phillips, Andrew L. Ellingson, Katherine Ferraris, Maria V. LeClair, Lindsay B. Mathenge, Clare Yoo, Young M. Thiese, Matthew S. Gerald, Lynn B. Solle, Natasha Schaefer Jeddy, Zuha Odame-Bamfo, Leah Mak, Josephine Hegmann, Kurt T. Gerald, Joe K. Ochoa, Jezahel S. Berry, Mark Rose, Spencer Lamberte, Julie Mayo Madhivanan, Purnima Pubillones, Felipe A. Rai, Ramona P. Dunnigan, Kayan Jones, John T. Krupp, Karl Edwards, Laura J. Bedrick, Edward J. Sokol, Brian E. Lowe, Ashley McLeland-Wieser, Hilary Jovel, Krystal S. Fleary, Deanna E. Khan, Sana M. Poe, Brandon Hollister, James Lopez, Joanna Rivers, Patrick Beitel, Shawn Tyner, Harmony L. Naleway, Allison L. Olsho, Lauren E.W. Caban-Martinez, Alberto J. Burgess, Jefferey L. Thompson, Mark G. Gaglani, Manjusha |
| author_sort | Fowlkes, Ashley L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8942308 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Centers for Disease Control and Prevention |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89423082022-03-31 Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 Fowlkes, Ashley L. Yoon, Sarang K. Lutrick, Karen Gwynn, Lisa Burns, Joy Grant, Lauren Phillips, Andrew L. Ellingson, Katherine Ferraris, Maria V. LeClair, Lindsay B. Mathenge, Clare Yoo, Young M. Thiese, Matthew S. Gerald, Lynn B. Solle, Natasha Schaefer Jeddy, Zuha Odame-Bamfo, Leah Mak, Josephine Hegmann, Kurt T. Gerald, Joe K. Ochoa, Jezahel S. Berry, Mark Rose, Spencer Lamberte, Julie Mayo Madhivanan, Purnima Pubillones, Felipe A. Rai, Ramona P. Dunnigan, Kayan Jones, John T. Krupp, Karl Edwards, Laura J. Bedrick, Edward J. Sokol, Brian E. Lowe, Ashley McLeland-Wieser, Hilary Jovel, Krystal S. Fleary, Deanna E. Khan, Sana M. Poe, Brandon Hollister, James Lopez, Joanna Rivers, Patrick Beitel, Shawn Tyner, Harmony L. Naleway, Allison L. Olsho, Lauren E.W. Caban-Martinez, Alberto J. Burgess, Jefferey L. Thompson, Mark G. Gaglani, Manjusha MMWR Morb Mortal Wkly Rep Full Report Centers for Disease Control and Prevention 2022-03-18 /pmc/articles/PMC8942308/ /pubmed/35298453 http://dx.doi.org/10.15585/mmwr.mm7111e1 Text en https://creativecommons.org/publicdomain/zero/1.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. |
| spellingShingle | Full Report Fowlkes, Ashley L. Yoon, Sarang K. Lutrick, Karen Gwynn, Lisa Burns, Joy Grant, Lauren Phillips, Andrew L. Ellingson, Katherine Ferraris, Maria V. LeClair, Lindsay B. Mathenge, Clare Yoo, Young M. Thiese, Matthew S. Gerald, Lynn B. Solle, Natasha Schaefer Jeddy, Zuha Odame-Bamfo, Leah Mak, Josephine Hegmann, Kurt T. Gerald, Joe K. Ochoa, Jezahel S. Berry, Mark Rose, Spencer Lamberte, Julie Mayo Madhivanan, Purnima Pubillones, Felipe A. Rai, Ramona P. Dunnigan, Kayan Jones, John T. Krupp, Karl Edwards, Laura J. Bedrick, Edward J. Sokol, Brian E. Lowe, Ashley McLeland-Wieser, Hilary Jovel, Krystal S. Fleary, Deanna E. Khan, Sana M. Poe, Brandon Hollister, James Lopez, Joanna Rivers, Patrick Beitel, Shawn Tyner, Harmony L. Naleway, Allison L. Olsho, Lauren E.W. Caban-Martinez, Alberto J. Burgess, Jefferey L. Thompson, Mark G. Gaglani, Manjusha Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 |
| title | Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 |
| title_full | Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 |
| title_fullStr | Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 |
| title_full_unstemmed | Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 |
| title_short | Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 |
| title_sort | effectiveness of 2-dose bnt162b2 (pfizer biontech) mrna vaccine in preventing sars-cov-2 infection among children aged 5–11 years and adolescents aged 12–15 years — protect cohort, july 2021–february 2022 |
| topic | Full Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942308/ https://www.ncbi.nlm.nih.gov/pubmed/35298453 http://dx.doi.org/10.15585/mmwr.mm7111e1 |
| work_keys_str_mv | AT fowlkesashleyl effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT yoonsarangk effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT lutrickkaren effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT gwynnlisa effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT burnsjoy effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT grantlauren effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT phillipsandrewl effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT ellingsonkatherine effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT ferrarismariav effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT leclairlindsayb effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT mathengeclare effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT yooyoungm effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT thiesematthews effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT geraldlynnb effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT sollenatashaschaefer effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT jeddyzuha effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT odamebamfoleah effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT makjosephine effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT hegmannkurtt effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT geraldjoek effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT ochoajezahels effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT berrymark effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT rosespencer effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT lambertejuliemayo effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT madhivananpurnima effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT pubillonesfelipea effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT rairamonap effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT dunnigankayan effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT jonesjohnt effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT kruppkarl effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT edwardslauraj effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT bedrickedwardj effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT sokolbriane effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT loweashley effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT mclelandwieserhilary effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT jovelkrystals effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT flearydeannae effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT khansanam effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT poebrandon effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT hollisterjames effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT lopezjoanna effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT riverspatrick effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT beitelshawn effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT tynerharmonyl effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT nalewayallisonl effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT olsholaurenew effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT cabanmartinezalbertoj effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT burgessjeffereyl effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT thompsonmarkg effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 AT gaglanimanjusha effectivenessof2dosebnt162b2pfizerbiontechmrnavaccineinpreventingsarscov2infectionamongchildrenaged511yearsandadolescentsaged1215yearsprotectcohortjuly2021february2022 |